TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05119439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone + 2 doses of misoprostol 800 mcg
Description: Will use a mifepristone-misoprostol regimen of: 200 mg mifepristone followed in 24-48 hours by a first dose of 800 µg misoprostol buccally and then in another 4 hours by a second dose of 800 µg misoprostol buccally. For buccal administration of misoprostol, participants will place 2 misoprostol tablets in each cheek and hold them for 20-30 minutes, after which they will swallow any remnants.
Study: NCT05286957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant tislelizumab and chemotherapy for MRD+ patients
Description: MRD+ patients receive adjuvant tislelizumab and chemotherapy while MRD- patients just is recommended receive adjuvant chemotherapy untill be detected MRD+~adjuvant tislelizumab and chemotherapy (cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant tislelizumab and chemotherapy for MRD+ patients
Description: MRD+ patients receive adjuvant tislelizumab and chemotherapy while MRD- patients just is recommended receive adjuvant chemotherapy untill be detected MRD+~adjuvant tislelizumab and chemotherapy (cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant tislelizumab and chemotherapy for MRD+ patients
Description: patients receive adjuvant tislelizumab and chemotherapy regardless of MRD status

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant chemotherapy for MRD- patients
Description: MRD- patients just be recommended receive adjuvant chemotherapy untill be detected cisplatin/carboplatin + paclitaxel or cisplatin/carboplatin + pemetrexed,dependent on tumor histology and at investigator's discretion, limited to ≤4 cycles
Study: NCT06214364

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Transcranial Direct Current Stimulation
Description: Active Anodal Transcranial Direct Current Stimulation (a-tDCS) will be applied over the Primary Motor Cortex of the affected or most affected hemisphere during 10 20 minute-sessions at 2 miliamps.~The tDCS stimulator device will be used by an experienced physical therapist by a saline-soak pair of surface electrodes. The anode electrode will be placed over C3 (EEG 10/20 system) and the cathode electrode over the contralateral supraorbital area (Fp2), in order to enhance the excitability of M1.~While the tDCS stimulation is administered, virtual reality upper limb exercises will be conducted. Virtual reality program will continue for another 20 minutes after the tDCS stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: The electrodes will be placed in the same position as for the Primary Motor Cortex stimulation, as in the experimental group. Current will be applied for 30 seconds in the beginning and at the end for securing the blinding.~While the sham tDCS stimulation is administered virtual reality upper limb exercises will be conducted. Virtual reality program will continue for another 20 minutes after the tDCS stimulation.
Study: NCT05532527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microwave ablation combined with Camrelizumab and chemotherapy
Description: Microwave ablation combined with Camrelizumab and chemotherapy
Study: NCT05486780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Window
Description: For the digital window, a regal brand, 43R654FC, 43-inch (109 cm) television was used. A three-dimensional frame was built to give the appearance of a window around the television. For the digital window, a regal brand, 43R654FC, 43-inch (109 cm) television was used. A three-dimensional frame was built to give the appearance of a window around the television. Data collection will be completed by the researcher completing the Day and Night Perception Form and the Richards Campbell Sleep Scale (Post-Test) on the 1st, 2nd, and 3rd days of post-op for the patients in the experimental group who are in the field of view of the digital window.
Study: NCT05842876

Intervention type: DEVICE
Intervention: Continuous Renal NIRS Monitoring
Description: Renal oxygenation data collected every 6 seconds

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard Clinical Care
Description: q6 h BP, q6 h Pulse ox, Echo at 24-72h

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard Clinical Care
Description: Renal oxygenation data collected every 6 seconds, q6 h BP, continuous Pulse ox, Echo at 12-72h

Intervention type: OTHER
Intervention: Satisfaction Survey
Description: Survey to assess which method of monitoring is preferred

Intervention type: OTHER
Intervention: Satisfaction Survey
Description: Survey to assess which method of monitoring is preferred
Study: NCT06521476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Oral acetazolamide 250 mg daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo daily for 7 days
Study: NCT06415721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial Magnetic Simulation
Description: 1 session of active continuous theta burst stimulation (3600 pulses, 110% RMT) will be delivered to the cortical region demonstrating maximal functional connectivity with the striatum during alcohol cue presentation. TMS will be delivered using the Magventure MagPro X100.
Study: NCT06506474

Intervention type: DIAGNOSTIC_TEST
Intervention: Provision of any of six different low-value health services for treatment of bronchiolitis
Description: This prospective observational will have six separate primary outcomes acting as exposures, (or interventions).The exposures are the the provision of any of the six low-value health services: 1) respiratory virus testing; 2) chest x-ray; 3) continuous pulse oximetry; 4) short-acting beta-agonists; 5) systemic corticosteroids; and 6) antibiotics.

Intervention type: DIAGNOSTIC_TEST
Intervention: Provision of any of six different low-value health services for treatment of bronchiolitis
Description: This prospective observational will have six separate primary outcomes acting as exposures, (or interventions).The exposures are the the provision of any of the six low-value health services: 1) respiratory virus testing; 2) chest x-ray; 3) continuous pulse oximetry; 4) short-acting beta-agonists; 5) systemic corticosteroids; and 6) antibiotics.
Study: NCT06415721

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: 1 session of sham continuous theta burst stimulation (3600 pulses, 110% RMT) will be delivered to the cortical region demonstrating maximal functional connectivity with the striatum during alcohol cue presentation. The MagVenture MagPro x100 is capable of administering a sham stimulation. The reverse side of the TMS coil is plated with a magnetic shield such that electromagnetic energy cannot stimulate the brain. The device offers compatibility with Transcutaneous Electrical Nerve Stimulation devices such that titrated electrical pulses can be delivered to the scalp location to mimic the sensation of a TMS pulse without stimulating the brain.
Study: NCT06122779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986435
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT04925401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Information brochure will be created on the basis of information given by the French pediatric network Courlygone and the French National Authority for Health.
Description: An information brochure on fever in children and how to deal with a paediatric febrile episode and usual medical management.
Study: NCT06392087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: Patients ≥ 18 years of age (using a waiver of consent process) Pain score ≥ 4 on the verbal numeric pain rating scale (NPRS) traumatic injury (defined as: physical injuries of sudden onset and severity which requires immediate medical attention) Unaltered (Glasgow Coma Scale (GCS) ≥ 14) Normotensive (systolic blood pressure ≥100) Treated and transported

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Patients ≥ 18 years of age (using a waiver of consent process) Pain score ≥ 4 on the verbal numeric pain rating scale (NPRS) traumatic injury (defined as: physical injuries of sudden onset and severity which requires immediate medical attention) Unaltered (Glasgow Coma Scale (GCS) ≥ 14) Normotensive (systolic blood pressure ≥100) Treated and transported
Study: NCT06134700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Surgery
Description: * Surgery will then proceed at either 8 - 10 or 12 - 15 mmHg pneumoperitoneum pressure depending on study group the patient falls into~* Port Placement~* Reflection of colon~* Isolation of ureterogonadal packet~* Upper pole dissection~* Hilar dissection~* Vessel clipping and division~* Dissection of kidney~* Delivery through either Pfannenstiel or iliac fossa incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Surgery
Description: * Surgery will then proceed at either 8 - 10 or 12 - 15 mmHg pneumoperitoneum pressure depending on study group the patient falls into~* Port Placement~* Reflection of colon~* Isolation of ureterogonadal packet~* Upper pole dissection~* Hilar dissection~* Vessel clipping and division~* Dissection of kidney~* Delivery through either Pfannenstiel or iliac fossa incision
Study: NCT05844046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab, tremelimumab, bevacizumab
Description: durvalumab, tremelimumab and bevacizumab will be administered in the respective arms either as up-front triple treatment or as combined treatment with durvalumab and tremelimumab followed by the addition of bevacizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab, tremelimumab, bevacizumab
Description: durvalumab, tremelimumab and bevacizumab will be administered in the respective arms either as up-front triple treatment or as combined treatment with durvalumab and tremelimumab followed by the addition of bevacizumab
Study: NCT05309447

Intervention type: OTHER
Intervention: data collection
Description: The study entails the collection of clinical, functional, radiological, and biomechanical data.

Intervention type: OTHER
Intervention: data collection
Description: The study entails the collection of clinical, functional, radiological, and biomechanical data.

Intervention type: OTHER
Intervention: data collection
Description: The study entails the collection of clinical, functional, radiological, and biomechanical data.
Study: NCT05679206

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography images
Description: Transthoracic echocardiographic (Vivid E95) performed in all included patients between three months and three years after delivery.~* Left ventricular ejection fraction,~* Left ventricular mass index,~* Septal and lateral mitral annular E-wave velocity assessed by tissue Doppler,~* Tricuspid annular plane systolic excursion,~* Left atrial volume index,~* Right ventricle to right atrium (RV/RA) gradient

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography images
Description: Transthoracic echocardiographic (Vivid E95) performed in all included patients between three months and three years after delivery.~* Left ventricular ejection fraction,~* Left ventricular mass index,~* Septal and lateral mitral annular E-wave velocity assessed by tissue Doppler,~* Tricuspid annular plane systolic excursion,~* Left atrial volume index,~* Right ventricle to right atrium (RV/RA) gradient

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour ambulatory blood pressure monitoring
Description: Twenty-four-hour ABPM performed between three months and three years after delivery using validated recorders (Spacelabs model 90217, USA)

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour ambulatory blood pressure monitoring
Description: Twenty-four-hour ABPM performed between three months and three years after delivery using validated recorders (Spacelabs model 90217, USA)
Study: NCT05766722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DORA AI
Description: Dora will phone patients on the day of cataract surgery (2 to 4 hours after discharge home) and again at postoperative week three. Dora calls made on the day of surgery will evaluate if the patient has any acute post-operative concerns like pain, and will prompt a postoperative day 1 visit if necessary. Calls to Dora at postoperative week three will result in either a follow-up to check refractive difficulties and/or confirmation of second eye surgery.
Study: NCT06125665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminophylline-Dexmedetomidine
Description: 10 minutes after endotracheal intubation, patients will receive intravenous (IV) bolus of dexmedetomidine 0.5 microgm/kg Lean body weight (LBW) over 15 min, followed immediately by intravenous infusion at 0.2 microgm /kg LBW/h and IV bolus of aminophylline of 5 mg/kg based on the ideal body weight (IBW) over 30 min, followed immediately by intravenous infusion at 0.6 mg/kg IBW/h. The study solutions will be diluted in 50 ml normal saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 10 minutes after endotracheal intubation, patients will receive intravenous (IV) bolus of dexmedetomidine 0.5 microgm/kg Lean body weight (LBW) over 15 min, followed immediately by intravenous infusion at 0.2 microgm /kg LBW/h. The study solutions will be diluted in 50 ml normal saline.
Study: NCT04879797

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of Maternal Safety Bundles
Description: In the second phase, implementation of the bundles will take place. During this phase investigators will conduct quarterly surveys with the health facilities to measure implementation progress, including an index of evidence-based practices. Investigators will conduct surveys with postpartum women to measure their patient experience. Surveys will be conducted using RedCap software. Participants will be given the opportunity to complete the survey online or if they prefer, a research assistant can call them to conduct the survey over the phone. Data on SMM will be collected through PELL
Study: NCT06084689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab + BI907828
Description: A treatment cycle consists of 3 weeks. Both treatments will be administered on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab + BI907828
Description: A treatment cycle consists of 3 weeks. Both treatments will be administered on Day 1 of each cycle.
Study: NCT04175964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ketogenic diet
Description: The ketogenic diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet for 8 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: caloric diet with Metformin
Description: The caloric diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet with Metformin for 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: caloric diet
Description: The caloric diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet for 8 weeks.
Study: NCT06302374

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR2001
Description: intramuscular injection
Study: NCT04879797

Intervention type: OTHER
Group type: OTHER
Intervention: Doula Services
Description: Investigators are evaluating doula services that are offered by two doula organizations at three hospitals.
Study: NCT05504109

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mitral valve replacement through full sternotomy approach.
Description: compare between Minimally Invasive Mitral Valve Replacement and Conventional Approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mitral valve replacement through right mini thoracotomy approach.
Description: compare between Minimally Invasive Mitral Valve Replacement and Conventional Approach
Study: NCT06302374

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR2001
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR2001
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR2001
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR2001
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR2001
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR2001
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR2001
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intramuscular injection
Study: NCT05046327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag 20 mg Oral Tablet
Description: Avatrombopag administered at a frequency to maintain a target platelet count between ≥50 and ≤150×10⁹/L
Study: NCT06173180

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOT
Description: In the Transobturator Tape-TOT operation, the anterior vaginal wall is incised 2 cm sagittal 1.5 cm below the urethra in the dorsal lithotomy position and the paraurethral areas are separated by sharp and blunt dissection and the ischiopubic bone is reached with the finger. The skin is incised so as to remain 1 cm lateral to the ischiopubic ramus on the line passing through the clitoris, and the synthetic tape is placed from outside to inside with special inclined trocars, passing under the urethra close to the medial part of the obturator foramen. Cystoscopy is not performed during the procedure. The vagen mucosa is sutured and the procedure is terminated by inserting a urethral foley catheter. The urethral catheter is removed on postoperative day 1 after the investigator evaluates the patient.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VACS-D
Description: The VACS-Minifiks procedure is a vaginal application of a natural tissue repair procedure whose efficacy has been proven in the abdominal route. The second difference is that the procedure is performed through a single incision instead of the three incisions used in the Transobturator Tape-TOT operation. Thus, the same goal will be achieved in a less invasive way without placing an artificial permanent implant. There is no difference in parameters such as anesthesia, operation time, and discharge time.
Study: NCT06302374

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HTIG
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HTIG
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid
Description: intramuscular injection
Study: NCT05615415

Intervention type: DRUG
Intervention: PET Tracer
Description: Standard radiopharmaceutical injected via intravenous catheter during PET-MR scanning.

Intervention type: DRUG
Intervention: PET Tracer
Description: Standard radiopharmaceutical injected via intravenous catheter during PET-MR scanning.

Intervention type: DRUG
Intervention: MRI Tracer
Description: Injected via intravenous catheter during PET-MR scanning.

Intervention type: DRUG
Intervention: MRI Tracer
Description: Injected via intravenous catheter during PET-MR scanning.

Intervention type: DEVICE
Intervention: 3T PET/MRI
Description: Used to evaluate neuroinflammation and cerebrovascular measures. Some MRI image acquisitions will employ work in progress (WIP) sequences, including ASL (Arterial Spin Labeling), Diffusion and T2-weighted EPI (DT2W), Golden-angle radial sparse parallel (GRASP) DCE-MRI, and Magnetization Transfer (MT) imaging.

Intervention type: DEVICE
Intervention: 3T PET/MRI
Description: Used to evaluate neuroinflammation and cerebrovascular measures. Some MRI image acquisitions will employ work in progress (WIP) sequences, including ASL (Arterial Spin Labeling), Diffusion and T2-weighted EPI (DT2W), Golden-angle radial sparse parallel (GRASP) DCE-MRI, and Magnetization Transfer (MT) imaging.
Study: NCT05941871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention - intervention group
Description: Low-calorie diet for 4 months with a different daily energy distribution according to the chronotype:~* Morning chronotype: 50% of kcal administered before lunch and 15% in the second part of the day (specifically: 40% at breakfast, 10% in the morning snack, 35% at lunch, 5% at afternoon snack and 10% at dinner)~* Evening chronotype: 15% of kcal given before lunch and 50% in the second half of the day (specifically: 10% of kcal at breakfast, 5% in the morning snack, 35% at lunch, 10% at snack time and 40% at dinner)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention - control group
Description: Group that will follow a low-calorie diet with a standard daily energy distribution (20% of kcal at breakfast, 10% in the morning snack, 35% at lunch, 10% at afternoon snack and 25% at dinner) for 4 months
Study: NCT06305884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bioelectric Impedance Analysis
Description: Undergo BI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Pedal an exercise bike

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photoplethysmography
Description: Undergo PPG

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06541431

Intervention type: OTHER
Intervention: Abdominal Drainage Fluid Collection
Description: Abdominal drainage fluid will be collected daily from the subjects until they are discharged from the hospital, or their abdominal/pelvic drain is removed, as determined by the treating surgeon.